- Email: [email protected]
Clinical improvements in facial photoaged skin using a novel oak quercetin topical preparation
P1613
P1615
Skin penetration of tretinoin in three concentrations as an agent for superficial chemical peeling Edileia Bagatin, PhD, Federal University of S~ao Paulo e UNIFESP, S~ao Paulo, Brazil; Erika Bontempo, PharmD, Faculty of Pharmaceutical Sciences of Ribeirao Pretom University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil; Nelson Aguiar, Jr, PharmD, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil; Patricia Maia Campos, PhD, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil; Tais Wagemaker, PharmD, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil
Clinical improvements in facial photoaged skin using a novel oak quercetin topical preparation Judith Nebus, Johnson and Johnson Consumer and Personal Products Worldwide, Skillman, NJ, United States; Katerina Vassilatou, Korres, Athens, Greece; Lena Philippou, Korres, Athens, Greece; Warren Wallo, Johnson and Johnson Consumer and Personal Products Worldwide, Skillman, NJ, United States
Background: Chemical peels are the application of caustic agents that destroy the superficial layers of the skin resulting in their loss and regeneration. The active principles most commonly used for the treatment of photoaging are topical retinoids, and tretinoin is considered the criterion standard. Tretinoin was reported as an agent for superficial peeling, but there are doubts about the stability, safety, efficacy, and penetration of formulations with high concentrations. Objective: To assess the skin penetration of tretinoin in three concentrations and two vehicles in formulations for superficial peeling. Methods: Franz cells in vitro permeation study, dermatomed porcine ear skin, and 10% methanol solution in the receptor compartment. The tretinoin concentration determination was made by high performance liquid chromatography (HPLC) on C18 column, detection at 343 nm, and methanol/water (98:2 v/v) as mobile phase. Results: The 0.25% formulation showed the largest amount of tretinoin penetration in the stratum corneum, epidermis, and dermis. The 5% solution showed greater skin penetration than the 5% cream formulation. Conclusion: The 0.25% formulation showed the highest percentage of penetration, indicating no advantage in using formulations with high concentrations of tretinoin to obtain the expected results for superficial peeling, with the possibility of fewer adverse effects.
Oak quercetin is a botanical containing active flavonoids that has shown multiple benefits to photoaged skin. Oak quercetin is a unique antioxidant that works on a specific protein pathway to help protect collagen and elastin, while ensuring the proper degradation of waste proteins in aging skin. This new novel natural extract has been formulated into a SPF 15 cream for topical facial use. A clinical study was performed on 32 female patients between the ages of 45 and 60 years old. Patients applied the oak quercetin treatment product twice a day for 60 days. Dermatologist assessments of smoothness, wrinkling, and skin radiance were performed at days 0, 30, and 60. Instrumental assessments of skin elasticity, wrinkling, and moisturization were also performed at these time points. Clinical and instrumental results showed that the oak quercetin cream significantly improved (P \ .05) various skin parameters including wrinkling, elasticity, smoothness, radiance, and moisturization—some parameters showing improvements as soon as 30 days after use. More than 90% of the patients perceived improvements in facial wrinkling, elasticity, and skin texture after 60 days of use. Cosmetic dermatologists now have a new gentle natural botanical, which works by a unique mechanism, showing excellent efficacy in improving various facial skin parameters in patients who exhibit photoaging. Commercial support: 100% sponsored by Johnson and Johnson Consumer Products Company.
Commercial support: None identified.
P1616
Doxycycline is a semisynthetic antibiotic that is derived from oxytetracycline. Although its use in dermatology has been known since 1966, this second generation tetracycline’s usage had been limited by its gastrointestinal disturbances and esophageal irritation. The advent of the delayed-release, enterically coated pellet of the hyclate form of doxycycline has reduced these untoward events and has made this antimicrobial increasingly helpful in dermatologic practice. The antimicrobial qualities of doxycycline are useful in the therapy of the pyodermas, anthrax, and lyme borreliosis, while this agent is also effective in the treatment of acne and rosacea. In addition, its antiinflammatory qualities have been used for the therapy of bullous disorders, sarcoidosis, and pyoderma gangrenosum.
Comparison of clinical improvements in facial photoaging of a topical system containing a bimineral complex and stabilized retinol versus a series of professional chemical peels Menas Kizoulis, Johnson and Johnson Consumer Companies, Skillman, NJ, United States; Warren Wallo, MS, Johnson and Johnson Consumer Companies, Skillman, NJ, United States Improving the signs of facial photoaging continues to be a primary dermatologic concern for many patients. Dermatologists can perform procedures such as chemically peeling the skin to visibly reduce the appearance of photodamaged skin. Superficial glycolic acid peels have been shown to improve skin texture, fine wrinkling, and hyperpigmentation. Still, some patients prefer to achieve these types of results by using daily topical skin care products. Recent reports highlight the antiaging benefits of a proprietary biomimetic signaling bimineral complex. Similarly, retinol has been shown in many studies to be an effective topical treatment for fighting the visible signs of facial photodamage. An 8-week, double-blind, randomized study was completed to compare the effects of daily topical usage of this novel bimineral/retinol combination to a series of glycolic acid peels to document clinical benefits on photoaged skin. In each cell, healthy female subjects 35 to 60 years of age exhibiting photodamage on the face, with moderate scores for two of the following four skin parameters: fine lines/wrinkles, mottled hyperpigmentation, tactile surface roughness, and lack of clarity were enrolled. Subjects using the 2-step bimineral/retinol system applied the test products to their full-face once per day in the evening for 8 weeks (n ¼ 33). In the second cell, a board-certified dermatologist administered a series of three peels (2 at 35% and 1 at 50% GA), one peel every 3 weeks over a period of 8 weeks (n ¼ 30). Dermatologist evaluation of the bimineral/retinol system indicated significant improvements (P \ .05) in facial skin texture and clarity after 1 week of use. Significant improvements (P\.05) in the appearance of mottled pigmentation, skin tone, fine lines, wrinkles, overall photodamage, and overall skin appearance occurred by the 4-week time point. By the conclusion of the 8-week clinical evaluation, the bimineral/retinol system revealed significant differences in numerous clinical parameters when compared to the skin benefits observed by the professionally administered series of three chemical peels. In conclusion, this clinical study showed that a regimen consisting of a bimineral complex and stabilized retinol was effective in improving the overall signs of facial photodamage, including improvements in skin texture, clarity, fine lines and wrinkles, pigmentation, and tone, while providing patients an effective alternative to chemical peels.
Commercial support: 90% sponsored by Warner-Chilcott.
Commercial support: Johnson and Johnson Consumer Companies.
P1614 Doxycycline in contemporary dermatologic practice Jennifer L. Parish, MD, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, United States; Hirak B. Routh, MBBS, Paddington Testing Company, Philadelphia, PA, United States; Lawrence Charles Parish, MD, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, United States
FEBRUARY 2011
J AM ACAD DERMATOL
AB73
P1615
Skin penetration of tretinoin in three concentrations as an agent for superficial chemical peeling Edileia Bagatin, PhD, Federal University of S~ao Paulo e UNIFESP, S~ao Paulo, Brazil; Erika Bontempo, PharmD, Faculty of Pharmaceutical Sciences of Ribeirao Pretom University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil; Nelson Aguiar, Jr, PharmD, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil; Patricia Maia Campos, PhD, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil; Tais Wagemaker, PharmD, Faculty of Pharmaceutical Sciences of Ribeirao Preto, University of S~ao Paulo e FCFRP, Ribeirao Preto, Brazil
Clinical improvements in facial photoaged skin using a novel oak quercetin topical preparation Judith Nebus, Johnson and Johnson Consumer and Personal Products Worldwide, Skillman, NJ, United States; Katerina Vassilatou, Korres, Athens, Greece; Lena Philippou, Korres, Athens, Greece; Warren Wallo, Johnson and Johnson Consumer and Personal Products Worldwide, Skillman, NJ, United States
Background: Chemical peels are the application of caustic agents that destroy the superficial layers of the skin resulting in their loss and regeneration. The active principles most commonly used for the treatment of photoaging are topical retinoids, and tretinoin is considered the criterion standard. Tretinoin was reported as an agent for superficial peeling, but there are doubts about the stability, safety, efficacy, and penetration of formulations with high concentrations. Objective: To assess the skin penetration of tretinoin in three concentrations and two vehicles in formulations for superficial peeling. Methods: Franz cells in vitro permeation study, dermatomed porcine ear skin, and 10% methanol solution in the receptor compartment. The tretinoin concentration determination was made by high performance liquid chromatography (HPLC) on C18 column, detection at 343 nm, and methanol/water (98:2 v/v) as mobile phase. Results: The 0.25% formulation showed the largest amount of tretinoin penetration in the stratum corneum, epidermis, and dermis. The 5% solution showed greater skin penetration than the 5% cream formulation. Conclusion: The 0.25% formulation showed the highest percentage of penetration, indicating no advantage in using formulations with high concentrations of tretinoin to obtain the expected results for superficial peeling, with the possibility of fewer adverse effects.
Oak quercetin is a botanical containing active flavonoids that has shown multiple benefits to photoaged skin. Oak quercetin is a unique antioxidant that works on a specific protein pathway to help protect collagen and elastin, while ensuring the proper degradation of waste proteins in aging skin. This new novel natural extract has been formulated into a SPF 15 cream for topical facial use. A clinical study was performed on 32 female patients between the ages of 45 and 60 years old. Patients applied the oak quercetin treatment product twice a day for 60 days. Dermatologist assessments of smoothness, wrinkling, and skin radiance were performed at days 0, 30, and 60. Instrumental assessments of skin elasticity, wrinkling, and moisturization were also performed at these time points. Clinical and instrumental results showed that the oak quercetin cream significantly improved (P \ .05) various skin parameters including wrinkling, elasticity, smoothness, radiance, and moisturization—some parameters showing improvements as soon as 30 days after use. More than 90% of the patients perceived improvements in facial wrinkling, elasticity, and skin texture after 60 days of use. Cosmetic dermatologists now have a new gentle natural botanical, which works by a unique mechanism, showing excellent efficacy in improving various facial skin parameters in patients who exhibit photoaging. Commercial support: 100% sponsored by Johnson and Johnson Consumer Products Company.
Commercial support: None identified.
P1616
Doxycycline is a semisynthetic antibiotic that is derived from oxytetracycline. Although its use in dermatology has been known since 1966, this second generation tetracycline’s usage had been limited by its gastrointestinal disturbances and esophageal irritation. The advent of the delayed-release, enterically coated pellet of the hyclate form of doxycycline has reduced these untoward events and has made this antimicrobial increasingly helpful in dermatologic practice. The antimicrobial qualities of doxycycline are useful in the therapy of the pyodermas, anthrax, and lyme borreliosis, while this agent is also effective in the treatment of acne and rosacea. In addition, its antiinflammatory qualities have been used for the therapy of bullous disorders, sarcoidosis, and pyoderma gangrenosum.
Comparison of clinical improvements in facial photoaging of a topical system containing a bimineral complex and stabilized retinol versus a series of professional chemical peels Menas Kizoulis, Johnson and Johnson Consumer Companies, Skillman, NJ, United States; Warren Wallo, MS, Johnson and Johnson Consumer Companies, Skillman, NJ, United States Improving the signs of facial photoaging continues to be a primary dermatologic concern for many patients. Dermatologists can perform procedures such as chemically peeling the skin to visibly reduce the appearance of photodamaged skin. Superficial glycolic acid peels have been shown to improve skin texture, fine wrinkling, and hyperpigmentation. Still, some patients prefer to achieve these types of results by using daily topical skin care products. Recent reports highlight the antiaging benefits of a proprietary biomimetic signaling bimineral complex. Similarly, retinol has been shown in many studies to be an effective topical treatment for fighting the visible signs of facial photodamage. An 8-week, double-blind, randomized study was completed to compare the effects of daily topical usage of this novel bimineral/retinol combination to a series of glycolic acid peels to document clinical benefits on photoaged skin. In each cell, healthy female subjects 35 to 60 years of age exhibiting photodamage on the face, with moderate scores for two of the following four skin parameters: fine lines/wrinkles, mottled hyperpigmentation, tactile surface roughness, and lack of clarity were enrolled. Subjects using the 2-step bimineral/retinol system applied the test products to their full-face once per day in the evening for 8 weeks (n ¼ 33). In the second cell, a board-certified dermatologist administered a series of three peels (2 at 35% and 1 at 50% GA), one peel every 3 weeks over a period of 8 weeks (n ¼ 30). Dermatologist evaluation of the bimineral/retinol system indicated significant improvements (P \ .05) in facial skin texture and clarity after 1 week of use. Significant improvements (P\.05) in the appearance of mottled pigmentation, skin tone, fine lines, wrinkles, overall photodamage, and overall skin appearance occurred by the 4-week time point. By the conclusion of the 8-week clinical evaluation, the bimineral/retinol system revealed significant differences in numerous clinical parameters when compared to the skin benefits observed by the professionally administered series of three chemical peels. In conclusion, this clinical study showed that a regimen consisting of a bimineral complex and stabilized retinol was effective in improving the overall signs of facial photodamage, including improvements in skin texture, clarity, fine lines and wrinkles, pigmentation, and tone, while providing patients an effective alternative to chemical peels.
Commercial support: 90% sponsored by Warner-Chilcott.
Commercial support: Johnson and Johnson Consumer Companies.
P1614 Doxycycline in contemporary dermatologic practice Jennifer L. Parish, MD, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, United States; Hirak B. Routh, MBBS, Paddington Testing Company, Philadelphia, PA, United States; Lawrence Charles Parish, MD, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, United States
FEBRUARY 2011
J AM ACAD DERMATOL
AB73